uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Longitudinal stability of CSF biomarkers in Alzheimer's disease
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Public Health and Caring Sciences. (Geriatrics)
Show others and affiliations
2007 (English)In: Neuroscience Letters, ISSN 0304-3940, E-ISSN 1872-7972, Vol. 419, no 1, 18-22 p.Article in journal (Refereed) Published
Abstract [en]

Biomarker levels in cerebrospinal fluid (CSF) may serve as surrogate markers for treatment efficacy in clinical trials of disease-modifying drugs against Alzheimer's disease (AD). A prerequisite, however, is that the marker is sufficiently stable over time in individual patients. Here, we tested the stability of the three established CSF biomarkers for AD, total tau (T-tau), tau phosphorylated at threonine 181 (P-tau181) and the 42 amino acid isoform of β-amyloid (Aβ42), over 6 months in a cohort of AD patients on stable treatment with acetylcholinesterase (AChE) inhibitors. Fifty-three patients completed the study, 29 men and 24 women, mean age (±S.D.) 76.1 ± 7.9 years. Mean levels of CSF biomarkers were very stable between baseline and endpoint, with coefficients of variation (CVs) of 4.4–6.1%. Intra-individual biomarker levels at baseline and endpoint were also highly correlated with Pearson r-values above 0.95 (p < 0.0001), for all three markers. We conclude that T-tau, P-tau and Aβ42 concentrations in CSF are remarkably stable over a 6-month period in individual AD patients. This suggest that these biomarkers may have a potential to identify and monitor very minor biochemical changes induced by treatment, and thus support their possible usefulness as surrogate markers in clinical trials with drug candidates with disease-modifying potential, such as secretase inhibitors, Aβ immunotherapy and tau phosphorylation inhibitors.

Place, publisher, year, edition, pages
2007. Vol. 419, no 1, 18-22 p.
Keyword [en]
Biomarkers, β-Amyloid, Cerebrospinal fluid (CSF), Clinical trials, Longitudinal, Tau protein
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-11010DOI: 10.1016/j.neulet.2007.03.064ISI: 000246815200005PubMedID: 17482358OAI: oai:DiVA.org:uu-11010DiVA: diva2:38778
Available from: 2008-04-14 Created: 2008-04-14 Last updated: 2011-01-28Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Lannfelt, LarsBasun, Hans
By organisation
Department of Public Health and Caring Sciences
In the same journal
Neuroscience Letters
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 183 hits
ReferencesLink to record
Permanent link

Direct link